Clinical Trial Update: Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating Rifamycin SV-MMX 600 mg tablets given two or three times daily in diarrhea-predominant irritable bowel syndrome (IBS-D).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diarrhea-predominant Irritable Bowel Syndrome

Drugs mentioned

• Rifamycin SV-MMX (rifamycin SV-MMX)

Snippet

Sponsor: Cosmo Technologies Ltd | Conditions: Diarrhea-predominant Irritable Bowel Syndrome | Phase 2 | Status: COMPLETED